ULK1 and breast carcinoma: Their activity was also detected in delphinidin-treated breast cancer cells; delphinidin promoted the activation of ULK1 and FOXO3a and this activation was enhanced by an increase in the dose of delphinidin (Figs. 6e, f and 7e, f).